Brexit - What will the impact be?

In Vivo

How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets. 

Topic Brexit Policy and regulation

HBW Insight

PAGB Looks To The Future As It Celebrates 100-Year Anniversary

Maximizing opportunities from digital technology, addressing environmental concerns and responding to the challenges of Brexit are among the Proprietary Association of Great Britain's top priorities as it enters its second century. The association invited guests from around the world to celebrate its centenary at a gala dinner in London on 17 June.

Topic Brexit Digital Health Strategy

Medtech Insight

UK To Demand 'Responsible Person' Be Physically Located In Country Under No-Deal Brexit

The recent no-deal Brexit notice from the UK government says that companies selling devices in the UK would need a "Responsible Person" in the UK if the firm is not based there. The government clarifies to Medtech Insight that such person must be physically present in the UK, and not simply have an address there.

Topic Brexit

Pink Sheet

The Tricky Task Of Bringing Smaller EU Countries Into The Fold

Clusters of excellence, competition as well as co-operation, Brexit, and aiming high. Danish Medicines Agency head Thomas Senderovitz talks national agencies and engagement in an interview with the Pink Sheet.

Topic Brexit Drug development landscape Drug approval

Medtech Insight

Medical Device Registration In UK Under A No Deal Brexit Questions Answered

The UK government is introducing new registration requirements for medical devices in the event of a no-deal Brexit. They will be rolled out according to the risk class of products. But some fundamental questions have arisen.

Topic Brexit Medtech

Scrip

Infographic: The Netherlands, A Small Country With Big Ideas

As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.

Topic Business strategies Brexit

Pink Sheet

Brexit Likely To Force Refocusing Of Ambitious EU Network Strategy

The European Medicines Agency and drug regulators throughout the EU are having to invest huge amounts of time and effort in dealing with the fall-out from Brexit - and it hasn't even happened yet. Plans for working together on bigger issues agreed on a few years ago will likely have to change, senior regulator Thomas Senderovitz tells the Pink Sheet.

Topic Brexit Business strategies

Scrip

No-Deal Brexit 'Very Bad' For Business And Patients

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.

Topic Brexit Business strategies

Pink Sheet

'Rule Out No-Deal Brexit,' BIA Tells Government

The BioIndustry Association wants the government to rule out a “no-deal” Brexit, saying it would be bad for patients and the life sciences sector.

Topic Brexit Business strategies Strategy